NBIX Neurocrine Biosciences Inc.

56.33
-0.36  -1%
Previous Close 56.69
Open 56.92
Price To book 14.41
Market Cap 4969526896
Shares 88,221,674
Volume 475,346
Short Ratio 9.71
Av. Daily Volume 882,857

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171075158
  2. 8-K/A [Amend] - Current report 171074016
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005147
  4. 8-K - Current report 171004935
  5. 8-K - Current report 17962133

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date for sNDA 80 mg capsules October 14, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 planned.
NBI-640756
Essential Tremor
NDA filing planned - license agreement with BIAL announced February 9, 2017.
Opicapone
Parkinson's disease
Phase 2 data released May 23 - primary endpoint not met.
INGREZZA
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due late 2017.
Elagolix
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia

Latest News

  1. See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
  2. Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress
  3. Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
  4. AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
  5. Behind Bioverativ’s Analyst Recommendations This September
  6. Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference
  7. Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82
  8. Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.
  9. Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT
  10. IHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two out of three available IHS Markit categories.
  11. IHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category.
  12. Featured Company News - Mylan Launches Avonza(TM) in India
  13. Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics
  14. NBIX: Strong Start to INGREZZA® Launch

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171075158
  2. 8-K/A [Amend] - Current report 171074016
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005147
  4. 8-K - Current report 171004935
  5. 8-K - Current report 17962133
  6. 8-K - Current report 17946129
  7. 8-K - Current report 17903367
  8. CT ORDER - Confidential treatment order 17882789
  9. 8-K - Current report 17866849
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827314